👉 The company recorded its first sale of rAAV to Genovac, a CRO and CMO.
💡 Agathos used the transfection process with three plasmids to produce the rAAV.
✅ The AE1-BHK cell line was developed by stable transfection of the BHK-21 cell line.
🔬 Agathos is working on developing AE1-BHK for biomanufacturing and improving ethical concerns regarding cell lines derived from aborted fetal tissue.
🌐 The company is collaborating with others to expand access to novel treatments through improved manufacturing materials and methods.
Introduction:
Agathos Biologics, based in Fargo, ND, has launched its recombinant adeno-associated virus (rAAV) production service using its proprietary cell line, AE1-BHK. This new service marks a significant milestone for the company, as it is the first sale of rAAV produced using triple transfection in a cell line other than HEK293. Agathos produced rAAV with a transgene sequence provided by Genovac using AE1-BHK and plans to assist clients in designing rAAV expression cassettes containing their gene of interest.
- Agathos Biologics has launched its rAAV production service using its AE1-BHK cell line.
- The company recorded its first sale of rAAV to Genovac, a CRO and CMO.
- Agathos produced rAAV using triple transfection in the AE1-BHK cell line, which is a new approach compared to the commonly used HEK293 cell line.
- The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line with the adenoviral E1 gene.
- Agathos plans to provide custom rAAV services, assisting clients in designing rAAV expression cassettes containing their gene of interest.
Conclusion:
Agathos Biologics has launched its rAAV production service, using a novel AE1-BHK cell line. This marks a significant milestone for the company, as it is the first sale of rAAV produced using triple transfection in a cell line other than HEK293. The AE1-BHK cell line offers an alternative approach to rAAV production and has the potential to improve biomanufacturing while addressing ethical concerns associated with cell lines derived from aborted fetal tissue. Agathos plans to collaborate with other industry partners to further develop AE1-BHK and expand access to novel gene therapies.
